Key takeaways
- Cost compounds. A daily NAD+ precursor is a meaningful recurring expense with no obvious stopping point.
- The feedback problem: nothing perceptible happens, so there is nothing reinforcing the habit.
- US regulatory status turned NMN into a supply question in 2022 and it has not fully resolved.
- Purity and label accuracy vary widely between suppliers, and buyers found out the hard way.
The feedback vacuum
The most common reason people stop is the simplest: nothing happens that they can feel. NMN is not a stimulant. Its proposed benefits are slow, systemic and largely invisible from the inside.
Habits survive on reinforcement. Caffeine reinforces immediately; a gym session reinforces within weeks. A supplement whose entire value proposition is a biomarker you are not measuring has no reinforcement loop at all, and eventually the bottle runs out and does not get reordered.
This applies to every longevity supplement including ours, which is exactly why we recommend measuring. A panel result is the only feedback loop this category can honestly offer.
Cost without a horizon
Quality NMN at a meaningful dose is a real monthly line item, and unlike a course of anything, there is no defined endpoint. The implied commitment is indefinite.
At some point most people run the arithmetic on annual spend and ask what they got. Without a measurement the true answer is "I don’t know", and "I don’t know" rarely survives a budget review.
The regulatory rupture
In 2022 the FDA took the position that NMN was excluded from the dietary-supplement definition, having been investigated as a drug. Major retailers delisted, supply became erratic, and buyers who had built a multi-year routine suddenly could not reliably reorder.
The situation has been contested since and remains unsettled. For a consumer the practical effect is the same regardless of who is right: uncertainty about whether the product will exist next year is corrosive to a habit meant to run for a decade.
The UK’s novel-foods framework created a parallel problem for British buyers, which is a large part of why so many of them started looking for an alternative.
Quality variance
Third-party testing of NMN products has repeatedly found actual content diverging from label claims, sometimes severely. For a compound that is expensive to synthesise properly, this is a predictable outcome in a market with light enforcement.
The consequence is a buyer paying premium prices with no way to verify what is in the capsule, which for a category asking people to trust invisible mechanisms is corrosive in a way that is hard to recover from.
Why I stopped taking NMN: what people move to
The common paths after NMN: stopping entirely, often the rational choice if nothing was being measured; switching to NR, a related precursor with a clearer regulatory position; moving to a different mechanism such as autophagy or oxidative-defence approaches; or stacking, adding rather than replacing.
If that is where you are, the move isn’t picking the next bottle. It is deciding what you would measure, and what result would make you stop. That question is more valuable than any product recommendation, including ours.
| Criterion | What it solves | What it leaves open |
|---|---|---|
| Stopping entirely | Removes a cost that had no measured return | The mechanism you were targeting goes unaddressed |
| Switching to NR | Same NAD+ pathway, clearer regulatory position | The same feedback problem: nothing perceptible |
| Changing mechanism | Targets damage or clearance instead of the coenzyme | A new evidence base to read before you trust it |
| Stacking | Keeps NAD+ support and adds a second lever | Two variables at once, so the result is uninterpretable |
What happens when you stop taking NMN, and what to measure next
The useful move once a bottle runs out is not choosing the next one. It is writing down the number you would track and the result that would make you stop. The biological-age article covers why one reading cannot do that job, and why two baselines are the minimum.
If you do buy something next, buy on a documented mechanism rather than a category label. The Bacillus F drops are $250 per 30-day protocol at 2 ml a day, which is a real recurring cost and deserves to be treated as one. What you can read before paying: patent WO2012060729 and the publications on the strain page, and the comet-assay panels on the Science page. If you arrived here by typing "why I stopped taking NMN", that record is the place to start.
- Pick the measurement first. A panel you will actually repeat beats a biomarker you admire.
- Run 90 days minimum before the second reading, against two baselines rather than one.
- Write the stopping rule down in advance. Deciding afterwards is how people stay subscribed for years.
- Compare mechanisms, not brands. Bacillus F vs NMN sets the two side by side.